Views
5 years ago

Treatment for Restless Legs Syndrome - AHRQ Effective Health ...

Treatment for Restless Legs Syndrome - AHRQ Effective Health ...

Treatment for Restless Legs Syndrome - AHRQ Effective Health

Comparative Effectiveness Review Number 86 Treatment for Restless Legs Syndrome

  • Page 2 and 3: Comparative Effectiveness Review Nu
  • Page 4 and 5: Preface The Agency for Healthcare R
  • Page 6 and 7: Peer Reviewers Philip M. Becker, M.
  • Page 8 and 9: children, or those with end-stage r
  • Page 10 and 11: Discussion.........................
  • Page 12 and 13: Executive Summary Introduction Rest
  • Page 14 and 15: Key Question 2. What are the harms
  • Page 16 and 17: Strength of the Body of Evidence We
  • Page 18 and 19: to 74) of randomized participants.
  • Page 20 and 21: evidence). In the maintenance trial
  • Page 22 and 23: Short-term adverse effects from tre
  • Page 24 and 25: 3.18]). 66 By 12 months, 21 of 31 s
  • Page 26 and 27: Table A. Overall strength of eviden
  • Page 28 and 29: Table C. Overall strength of eviden
  • Page 30 and 31: a dose effect for the outcomes of I
  • Page 32 and 33: Table D. Future research recommenda
  • Page 34 and 35: 14. Atkins D, Chang S, Gartlehner G
  • Page 36 and 37: 47. Bayard M, Bailey B, Acharya D,
  • Page 38 and 39: Introduction Overview Restless legs
  • Page 40 and 41: Table 1. Pharmacologic treatments f
  • Page 42 and 43: Table 2. Methods of assessment (con
  • Page 44 and 45: treatment-related harms and adheren
  • Page 46 and 47: Figure 1. Analytical framework KQ =
  • Page 48 and 49: Table 3. Inclusion criteria Domain
  • Page 50 and 51: imply that the included studies wer
  • Page 52 and 53:

    Description of Included Studies Of

  • Page 54 and 55:

    (low-strength evidence). 21 Strengt

  • Page 56 and 57:

    IRLS-Mean Change From Baseline (Fig

  • Page 58 and 59:

    enacarbil therapy were significantl

  • Page 60 and 61:

    weeks. Near-infrared light treatmen

  • Page 62 and 63:

    • One small crossover trial repor

  • Page 64 and 65:

    months to 10 years reported augment

  • Page 66 and 67:

    Table 4. Outcomes evaluated in plac

  • Page 68 and 69:

    Table 6. Overall strength of eviden

  • Page 70 and 71:

    Figure 3. Efficacy outcomes for tre

  • Page 72 and 73:

    Figure 4. Efficacy outcomes for tre

  • Page 74 and 75:

    Figure 6. Efficacy outcomes for tre

  • Page 76 and 77:

    Figure 8. Efficacy outcomes for tre

  • Page 78 and 79:

    Table 10. Overall strength of evide

  • Page 80 and 81:

    Figure 10. Efficacy outcomes for tr

  • Page 82 and 83:

    Table 11. Long-term harms with phar

  • Page 84 and 85:

    Table 12. Strength of evidence for

  • Page 86 and 87:

    Figure 13. Short-term harms of trea

  • Page 88 and 89:

    Figure 15. Short-term harms of trea

  • Page 90 and 91:

    Figure 17. Patients with ≥1 adver

  • Page 92 and 93:

    Discussion The primary intent of th

  • Page 94 and 95:

    effects suggest that for many RLS p

  • Page 96 and 97:

    Table 15. Future research recommend

  • Page 98 and 99:

    18. Lettieri CJ, Eliasson AH. Pneum

  • Page 100 and 101:

    51. Ferini-Strambi L. Restless legs

  • Page 102 and 103:

    Acronyms and Abbreviations AHRQ Age

  • Page 104 and 105:

    Appendix B. Excluded Studies 1. Bli

  • Page 106 and 107:

    40. Pieta J, Millar T, Zacharias J,

  • Page 108 and 109:

    Appendix C. Table 2. Summary of stu

  • Page 110 and 111:

    Appendix C. Table 4. Summary of stu

  • Page 112 and 113:

    Appendix D. Table 2. Individual Stu

  • Page 114 and 115:

    Study Design: crossover Duration: t

  • Page 116 and 117:

    Study Characteristics and Design ti

  • Page 118 and 119:

    Study Characteristics and Design St

  • Page 120 and 121:

    Study Characteristics and Design St

  • Page 122 and 123:

    Study Characteristics and Design St

  • Page 124 and 125:

    Study Characteristics and Design St

  • Page 126 and 127:

    Study Characteristics and Design St

  • Page 128 and 129:

    Study Characteristics and Design Ge

  • Page 130 and 131:

    Appendix E. Table 2. Evidence Table

  • Page 132 and 133:

    Study Characteristics and Design St

  • Page 134 and 135:

    Study Characteristics and Design In

  • Page 136 and 137:

    Appendix E. Table 3. Evidence Table

  • Page 138 and 139:

    Appendix E. Table 5. Evidence Table

  • Page 140 and 141:

    Study Characteristics and Design Du

  • Page 142 and 143:

    Study Characteristics and Design St

  • Page 144 and 145:

    Study Characteristics and Design pa

  • Page 146 and 147:

    Appendix F. Outcomes Tables Appendi

  • Page 148 and 149:

    Author year Kushida, 2008 8 Trenkwa

  • Page 150 and 151:

    Author year Study Duration (weeks)

  • Page 152 and 153:

    Appendix F. Table 5. International

  • Page 154 and 155:

    Appendix F. Figure 1. IRLS Remitter

  • Page 156 and 157:

    IRLS Responders (≥50% score reduc

  • Page 158 and 159:

    Patients with ≥1 serious adverse

  • Page 160 and 161:

    Application site reactions (Rotigot

  • Page 162 and 163:

    Somnolence Dopamine agonists Placeb

  • Page 164 and 165:

    Appendix. F. Figure3. Efficacy and

  • Page 166 and 167:

    Unsteadiness/dizziness Study or Sub

  • Page 168 and 169:

    Headache Study or Subgroup Events 2

  • Page 170 and 171:

    RSL-QoL Dopamine agonists Placebo S

  • Page 172 and 173:

    Vomiting Dopamine agonists Placebo

  • Page 174 and 175:

    Appendix F. Figure 5. Efficacy and

  • Page 176 and 177:

    Augmentation Study or Subgroup Tren

  • Page 178 and 179:

    Nausea Dopamine agonist Placebo Ris

  • Page 180 and 181:

    Fatigue Dopamine agonist Placebo Ri

  • Page 182 and 183:

    Appendix F. Table 10a. Self-rated q

  • Page 184 and 185:

    Appendix F. Table 13. Self-rated qu

  • Page 186 and 187:

    Appendix F. Table 14. Patient globa

  • Page 188 and 189:

    Trenkwalder, 2008 10 29 Placebo 54.

  • Page 190 and 191:

    Trenkwalder, 2008 10 96/341 (28.2)

  • Page 192 and 193:

    Appendix G. Table 3 Specific advers

  • Page 194 and 195:

    Appendix G. Table 5 Adverse effects

  • Page 196 and 197:

    Appendix G. Table 9 Specific advers

  • Page 198 and 199:

    19. Winkelman JW, Bogan RK, Schmidt

Restless Legs Syndrome: Restless Legs Syndrome
Registries for Evaluating Patient Outcomes - AHRQ Effective Health ...
Treatment Options for Rotator Cuff Tears - AHRQ Effective Health ...
Treatment Options for Rotator Cuff Tears - AHRQ Effective Health ...
Non-surgical Treatments for Urinary Incontinence - AHRQ Effective ...
Renal Artery Stenosis Treatments - AHRQ Effective Health Care ...
Gestational Diabetes - AHRQ Effective Health Care Program
Rheumatoid Arthritis Medicines - AHRQ Effective Health Care Program
Gestational Diabetes - AHRQ Effective Health Care Program ...
Therapies for Treatment- Resistant Depression - AHRQ Effective ...
Medicines for Type 2 Diabetes - AHRQ Effective Health Care Program
Gestational Diabetes - AHRQ Effective Health Care Program ...
Treating High Cholesterol - AHRQ Effective Health Care Program
Chronic Fatigue Syndrome: diagnosis, treatment and care ... - KCE
The Treatment of Restless Legs Syndrome and Periodic ... - Sleep
Dopamine agonists for restless legs syndrome - Update Software
Treatment of restless legs syndrome - The Movement Disorder Society
Successful Treatment of Recalcitrant Restless Legs Syndrome With ...
Physostigmine for the Acute Treatment of Restless Legs Syndrome
Restless legs syndrome - IAFP.com
Oxcarbazepine Treatment of Restless Legs Syndrome
Algorithms for the diagnosis and treatment of restless legs syndrome ...
Current Treatments for Restless Leg Syndrome - FreeCE
Diagnosis and Management of Restless Legs Syndrome
Sequential Compression Devices for Treatment of Restless Legs ...
European Restless Legs Syndrome Study Group ... - Eurlssg.org
Oral Ketamine: A Promising Treatment for Restless Legs Syndrome
Pramipexole in the Management of Restless Legs Syndrome ... - Sleep
EFNS guidelines on management of restless legs syndrome and ...